Phaseline

Companies › Teva Branded Pharmaceutical Products R&D

Teva Branded Pharmaceutical Products R&D: clinical trials, targets and expected readouts

6 active drug programs in 9 registered trials: 4 Phase 2, 3 Phase 1, 2 Phase 3; Immunology, Respiratory, Neurology, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TEV-56248
Fixed-dose combination of inhaled corticosteroid (fluticasone propionate) and beta-2 agoni
ADRB2Phase 3AsthmaDec 2026
Fluticasone Propionate
Glucocorticoid receptor agonist
NR3C1Phase 3Asthma–
TEV-56286
alpha-synuclein aggregation inhibitor
SNCAPhase 2Multiple System Atrophy; Healthy VolunteersJan 2027
TEV-48574
TNF-α antagonist monoclonal antibody (duvakitug)
TNFPhase 2Crohn DiseaseJan 2027
TEV-53408–Phase 2Celiac Disease; VitiligoSep 2027
TEV-56278–Phase 1Advanced Solid TumorsMay 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06664619Fluticasone PropionatePhase 3AsthmaRespiratoryOct 2026
NCT06052267TEV-56248Phase 3AsthmaRespiratoryDec 2026
NCT07674940TEV-56286Phase 1Healthy VolunteersOtherJan 2027
NCT05668013TEV-48574Phase 2Crohn DiseaseImmunologyJan 2027
NCT06807463TEV-53408Phase 2Celiac DiseaseGastroenterologySep 2027
NCT06568237TEV-56286Phase 2Multiple System AtrophyNeurologySep 2027
NCT06625177TEV-53408Phase 1VitiligoImmunologyApr 2028
NCT07197866TEV-56286Phase 2Multiple System AtrophyNeurologyMay 2029
NCT06480552TEV-56278Phase 1Advanced Solid TumorsOncologyMay 2029

From the company's SEC filings

Complete response letters from FDA

Targets

SNCA (1) ADRB2 (1) TNF (1) NR3C1 (1)

Companies with the same targets

Chiesi Farmaceutici AstraZeneca Corcept Therapeutics GSK AC Immune Regeneron Pharmaceuticals Roche XingImaging Lunan Better Pharmaceutical Actimed Therapeutics

Companies built like this

Sunshine Guojian Pharmaceutical (Shanghai) Guangdong Hengrui Pharmaceutical Chiesi Farmaceutici Optinose US Pacira Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.